google-site-verification: googlec7193c3de77668c9.html

Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer

[
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to the results of a Phase III IidERA trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.


Source link

Advertisements
Views: 2

See also  2025 Women's Rugby World Cup: How Ellie Kildunne helped England 'run the game' in second half

Check Also

AI-guided drug search flags folic acid for diabetic wound healing

[ Researchers from the National University of Singapore (NUS) have developed an AI-guided workflow that …

Blood pressure swings over 24 hours tied to poorer brain health

[ Credit: Antoni Shkraba Studio from Pexels Frequent changes in blood pressure could affect cognitive …

An 'intelligent tattoo' to detect skin cancer before it appears

[ Detecting melanoma before it becomes visible is a major challenge in dermatology. Now, with …

Leave a Reply

Available for Amazon Prime
Lexonads | free ad network | automated website traffic.